摘要
目的观察紫杉醇联合革酸铂作为IV期非小细胞肺癌化疗方案与紫杉醇联合顺铂方案的近期疗效以及毒副作用比较。方法IV期非小细胞肺癌者64例，经随机平均分为两组。两组的紫杉醇剂量60-80g／m^2第1天、第8天、第15天静脉滴注，一疗程总量135mg／m^2。其中治疗组草酸铂130mg／m^2静脉滴注，第1天，每4周重复。对照组顺铂75mg／m^2静脉滴注，第1天，每4周重复。连续化疗2周期，化疗后4周评价化疗疗效及比较毒副作用。结果治疗完全缓解2例，部分缓解13例，稳定14例，进展3例，有效率为46．9％。对照组完成缓解2例，部分缓解12例，稳定14例，进展4例，有效率为43．8％。治疗组有效率高于对照组，经过统计分析无显著性差异（P〉0．05）。治疗组的神经毒性较对照组明显（P〈0．05），对照组恶心呕吐反应和肝肾毒性较治疗组明显（P〈0．05）。两组的血液系统毒性相似（P〉0．05）。结论紫杉醇联合草酸铂作为IV期非小细胞肺癌化疗方案与紫杉醇联合顺铂方案比较近期疗效相当，胃肠道反应和肝肾毒性较轻，神经毒性较大。
Objective to evaluate the short term efficacy and side effect between paclitaxel plus Oxaliplatin regime and paclitaxel plus cisplatin regime. Methods 64 patients with iv stage non small lung caner were divided into the experiment group and the control group randomly. The total dose of paclitaxel were 135 mg/m^2in each cycle and in each group. The experiment group used oxaliplatin 130mg/ m^2, （intravenous infusion, d1）, four weeks for a cycle. The control group used cisplatin 75mg/m^2, （intravenous infusion, dl）, four weeks for a cycle. The two chemotherapy continued for two cycles. To evaluate the efficacy and safety after four weeks when the chemotherapy were finished. Resuls the overall response rate in experiment group was 46.9% for CR2, PR,3, SD,4, PD3, respectively, The overall response rate in control group was 43.8% for CR2, PR12, SD14, PD 4 The effective rate of experiment group is higher than that of control group, but without statistic significant different （P〉0.05）.The neural toxicity in experiment group is higher than fhat of control group（P〈0.05）.The nausea and vomiting in the control group is significant higher than that of experiment group（P〈0.05）.The side effect of blood in two group were similarly （P〉0.05）.Conclusion the chemotherapy of pacliaxel plus cisplatin and paclitaxel plus oxaliplatin were the nearly the same, but the latter with lower emesis, nausea and liver and renal toxicity, however it has higher neural toxicity.
出处
《国际医药卫生导报》
2007年第2期57-60,共4页
International Medicine and Health Guidance News
关键词
非小细胞肺癌
紫杉醇
顺铂
草酸铂
non-small lung cancer pacliaxel cisplatin oxalipliatin
